Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robbert G van der Most

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Journal of Immunological Methods|February 12, 2004
Three-color flow cytometry detection of virus-specific CD4+ and CD8+ T cells in the catJolanda D F de Groot-Mijnes, Robbert G van der Most, Jessica M van Dun, et al.
Virology|May 30, 2006
Characterization of the CD8+ T cell responses directed against respiratory syncytial virus during primary and secondary infection in C57BL/6 miceMichaël V Lukens, Erwin A W Claassen, Patricia M A de Graaff, et al.
Science Translational Medicine|November 12, 2020
Transcriptional profiles of adjuvanted hepatitis B vaccines display variable interindividual homogeneity but a shared core signatureLaurane De Mot, Viviane Bechtold, Vanesa Bol, et al.
The Journal of Experimental Medicine|June 2, 2010
Innate immunity defines the capacity of antiviral T cells to limit persistent infectionDaniel M Andrews, Marie J Estcourt, Christopher E Andoniou, et al.
Plos One|September 12, 2009
Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growthRobbert G van der Most, Andrew J Currie, Amanda L Cleaver, et al.
Immunity|May 13, 2008
Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccinesJoseph D Miller, Robbert G van der Most, Rama S Akondy, et al.
Virology|August 11, 2004
HLA-DP4 presents an immunodominant peptide from the RSV G protein to CD4 T cellsPatricia M A de Graaff, Jojanneke Heidema, Martien C Poelen, et al.
The Lancet. Infectious Diseases|June 3, 2026
Safety and immunogenicity of mRNA-based mpox vaccine candidate BNT166a: an open-label, dose-escalation, first-in-human trialFrank Bähner, Saul N Faust, Leela R L Davies, et al.
Cell Reports|September 5, 2024
Acute and persistent responses after H5N1 vaccination in humansRichard Apps, Angélique Biancotto, Julián Candia, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Journal of Immunological Methods|February 12, 2004
Three-color flow cytometry detection of virus-specific CD4+ and CD8+ T cells in the catJolanda D F de Groot-Mijnes, Robbert G van der Most, Jessica M van Dun, et al.
Virology|May 30, 2006
Characterization of the CD8+ T cell responses directed against respiratory syncytial virus during primary and secondary infection in C57BL/6 miceMichaël V Lukens, Erwin A W Claassen, Patricia M A de Graaff, et al.
Science Translational Medicine|November 12, 2020
Transcriptional profiles of adjuvanted hepatitis B vaccines display variable interindividual homogeneity but a shared core signatureLaurane De Mot, Viviane Bechtold, Vanesa Bol, et al.
The Journal of Experimental Medicine|June 2, 2010
Innate immunity defines the capacity of antiviral T cells to limit persistent infectionDaniel M Andrews, Marie J Estcourt, Christopher E Andoniou, et al.
Plos One|September 12, 2009
Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growthRobbert G van der Most, Andrew J Currie, Amanda L Cleaver, et al.
Immunity|May 13, 2008
Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccinesJoseph D Miller, Robbert G van der Most, Rama S Akondy, et al.
Virology|August 11, 2004
HLA-DP4 presents an immunodominant peptide from the RSV G protein to CD4 T cellsPatricia M A de Graaff, Jojanneke Heidema, Martien C Poelen, et al.
The Lancet. Infectious Diseases|June 3, 2026
Safety and immunogenicity of mRNA-based mpox vaccine candidate BNT166a: an open-label, dose-escalation, first-in-human trialFrank Bähner, Saul N Faust, Leela R L Davies, et al.
Cell Reports|September 5, 2024
Acute and persistent responses after H5N1 vaccination in humansRichard Apps, Angélique Biancotto, Julián Candia, et al.
Pageof 4